TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01634009

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy-based RUTF (in double blind design)
Description: Soy-based RUTF will be given in double blind manner
Study: NCT01712087

Intervention type: DEVICE
Intervention: MedStream Programmable Infusion System
Description: Intrathecal Infusion of Baclofen in the Treatment of Spasticity
Study: NCT03515434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
Study: NCT02623868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Cap.
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Cap.
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Cap.
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.
Study: NCT02960139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test- Treatment with Sylys Surgical Sealan
Description: Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
Study: NCT03515434

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study: NCT01085903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Submerging each participant's foot into ice water (36-44 F) for 50 seconds.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
Study: NCT04058119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body therapies
Description: Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
Study: NCT03740607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Healthcare virtual reality software implemented during peripheral intravenous catheter placement

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral intravenous catheter placement
Description: Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous catheter placement
Description: Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
Study: NCT01085903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post CPS
Description: 20 minutes following the CPS condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post CPS
Description: 20 minutes following the CPS condition.
Study: NCT00551720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
Study: NCT02044159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
Study: NCT00243230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc 30 mg
Description: Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc 30 mg
Description: Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc 20 mg
Description: Two tablets of vicriviroc 10 mg once daily for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three tablets of placebo once daily for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two tablets of placebo once daily for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background ART Regimen
Description: An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background ART Regimen
Description: An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background ART Regimen
Description: An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background ART Regimen
Description: An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir.
Study: NCT02467803

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapula mobilization

Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder ROM exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder ROM exercises
Study: NCT01085903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: Follow up testing occurred at 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: Follow up testing occurred at 3 months
Study: NCT03622606

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right Language screening test (R-LAST)
Description: Validation of the Right Language screening test in acute and subacute phase of right stroke
Study: NCT01137084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solu medrol
Description: total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a steroid-free immunosuppression protocol
Description: receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
Study: NCT00808873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: socio-educational intervention
Description: brief mental health education and 6 follow-up visits
Study: NCT02269111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW-MRI
Study: NCT01329133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation (DBS)
Description: In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation (DBS)
Description: In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
Study: NCT02485886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BMV101
Description: 68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
Study: NCT02269111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemical exchange saturation transfer magnetic resonance imaging
Description: Undergo CEST-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic susceptibility contrast-enhanced magnetic resonance imaging
Description: Undergo DSC-MRI
Study: NCT01539031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg
Study: NCT03200457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1,5 Tesla abdominal MRI
Description: Measurement of the fat and iron

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla abdominal MRI
Description: Measurement of the fat and iron
Study: NCT03153215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
Study: NCT02679248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neo40 Daily®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00038701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-470
Study: NCT00152815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antioxidant vitamin E
Description: Vitamin E 800IU per day for 12 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight reduction and exercise
Description: Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
Study: NCT01675531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targin
Description: Single arm for Targin
Study: NCT01539031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2020
Description: Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg
Study: NCT04505800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan supplement
Description: * Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltose
Description: Maltose
Study: NCT02662751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Imaging Assessment
Description: Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Imaging Assessment
Description: Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDWBA first (CT scan)
Description: Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient.
Study: NCT02383784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low GI index diet
Description: Low glycemic index diet
Study: NCT01037504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
Study: NCT00660478

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor
Description: Comparison of two different drug eluting coronary stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher Select
Description: Comparison of two different drug eluting coronary stents
Study: NCT04761237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDET)
Description: Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDET)
Description: Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
Study: NCT01955694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT02876471

Intervention type: OTHER
Group type: OTHER
Intervention: CPAP
Description: OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
Study: NCT02886741

Intervention type: OTHER
Group type: OTHER
Intervention: Quality Improvement Campaign
Description: How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty.
Study: NCT00494442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral